bpc 157 safety research BPC-157: Interesting Biology, Limited Clinical Proof You may have seen BPC-157

Deferasirox nephrotoxicity can be more common in the elderly

Unlike hormones or anabolic agents, BPC-157 is non-hormonal, non-steroidal, and does not disrupt natural endocrine function

The approach is also compatible with the controlled production in stirred tank bioreactors as recently demonstrated for cardiac and hematopoietic lineages 77,78 and will provide the field with a potentially game-changing resource to allow the development of clinical as well as screening platforms where the requirement will be in the millions of organoids rather than todays laboratory scale

Phase Cag introduction Weeks 9-12 Retatrutide 4 mg/week (hold) Cagrilintide 0.25 mg/week Notes Add cagrilintide at the lowest dose

This last factoid suggests it likely wouldnt work as well in younger patients who already have maximally sensitive HGH receptors on their cells